There was a higher incidence of myocardial ischemia in the levosimendan group at 14 days than in the placebo group ( 11.2 vs. 7.5 % , HR 1.510 , p = 0.435 ) , but between 15 and 180 days , it was significantly lower in the levosimendan group than in the placebo group ( 3.8 vs. 13.8 % , HR 0.261 , p = 0.036 ) .